Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Progressive Corp (PGR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Progressive Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Progressive Corp trades at $207 (market cap $123.45B). The key difference: Progressive Corp is far larger — about 4.2× Alnylam Pharmaceuticals, Inc.'s market cap, and Progressive Corp pays a 6.55% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | PGR | |
|---|---|---|
Market Cap | $29.60B | $123.45B |
Sector | Health | Financials |
52-Week High | $491.22 | $252.68 |
52-Week Low | $205.48 | $190.40 |
Enterprise Value | $27.56B | $131.66B |
Dividend Yield | — | 6.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Progressive (PGR) trades at $207.58, down 2.98% on the day, as technical indicators signal a bearish trend. Fundamentally, the company shows strong revenue growth from $49.6B in 2022 to $87.6B in 2025, with net income margins expanding to 12.85%. Recent Q2 2026 earnings beat estimates at $4.85 per share, though Q1 2026 missed expectations. Analyst consensus remains mixed with a $231.20 price target, representing 11.4% upside potential from current levels.
The stock presents a value opportunity with a P/E of 10.65 below industry averages, supported by robust cash flow generation and expanding profitability. Key risks include competitive pressures in insurance markets and potential margin compression from growth investments. Institutional ownership remains substantial despite recent portfolio adjustments by some funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →
